Patent application number | Description | Published |
20080200453 | Methods of treating metabolic syndrome using dopamine receptor agonists - The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier. | 08-21-2008 |
20080293735 | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes - The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient. | 11-27-2008 |
20090137598 | METHOD OF TREATING METABOLIC DISORDERS AND DEPRESSION WITH DOPAMINE RECEPTOR AGONISTS - This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant. | 05-28-2009 |
20090137599 | Methods of identifying responders to dopamine agonist therapy - The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites:dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has blood pressure of greater than about 135/85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy. | 05-28-2009 |
20090143390 | Parenteral Formulations of Dopamine Agonists - This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents_useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics. | 06-04-2009 |
20100035886 | PARENTERAL FORMULATIONS OF DOPAMINE AGONISTS - This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics. | 02-11-2010 |
20110136817 | Methods of identifying responders to dopamine agonist therapy - The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites:dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has blood pressure of greater than about 135/85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy. | 06-09-2011 |
20110195970 | Methods of identifying and treating responders to dopamine agonist therapy - The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites: dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has hypertension. The present invention is also directed to treating identified patients with dopamine agonist therapy. | 08-11-2011 |
20110195971 | Methods of identifying responders to dopamine agonist therapy - The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites: dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or said patient has hypertriglyceridemai and/or hypertension . The present invention is also directed to treating identified patients with dopamine agonist therapy. | 08-11-2011 |
20120142582 | Combination of Dopamine Agonists Plus First Phase Secretagogues for the Treatment of Metabolic Disorders - The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge. | 06-07-2012 |
20130197005 | Parenteral Formulations Of Dopamine Agonists - This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics. | 08-01-2013 |
20130274246 | Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes - The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic and/or serotonin neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient. | 10-17-2013 |
20130287848 | Bromocriptine Formulations - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes. | 10-31-2013 |
20140031359 | Method Of Treating Metabolic Disorders And Depression With Dopamine Receptor Agonists - This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant. | 01-30-2014 |
20140051685 | THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDIABETES - The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. | 02-20-2014 |
20140187560 | BROMOCRIPTINE FORMULATIONS - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycerine control in the treatment of type 2 diabetes. | 07-03-2014 |
20140249136 | Parenteral Formulations of Dopamine Agonists - This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics. | 09-04-2014 |
20140342975 | Therapeutic Process For The Treatment Of The Metabolic Syndrome And Associated Metabolic Disorders - The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens. | 11-20-2014 |
20150024995 | Combination Of Dopamine Agonists Plus First Phase Insulin Secretagogues For The Treatment Of Metabolic Disorders - The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge. | 01-22-2015 |
20150335641 | Method Of Treating Metabolic Disorders And Depression With Dopamine Receptor Agonists - This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant. | 11-26-2015 |
Patent application number | Description | Published |
20090208692 | LIMITED LIFE OPTICAL MEDIA - Optical media of a limited usable life are disclosed. The invention relates to chemical formulations and methods and processes for creating time limiting mechanisms for the inclusion in optical media thereby providing optical media with a limited usable life in which encoded information may be accessed, played and/or read for a prescribed limited time. The invention provides formulations and methods for corrosion of and/or the corrosive degradation of a reflective layer(s) and/or reflective material of optical media such that the encoded information stored on an optical medium can not longer be read by a reading beam. | 08-20-2009 |
20090262623 | OPTICAL MEDIA FORMAT - Apparatuses, products, devices and methods, of manufacture consistent with the invention include optically readable media with at least one mechanism, chemical, agent, and/or process for limiting the time period that at least a portion of encoded information can be read and/or accessed by an optical beam and/or reader capable of reading the encoded information. | 10-22-2009 |
20120080613 | Photolytically and Environmentally Stable Multilayer Structure for High Efficiency Electromagnetic Energy Conversion and Sustained Secondary Emission - A multilayer structure for sustained conversion of a primary electromagnetic radiation into another electromagnetic radiation characterized by a spectrum of a higher average wavelength is disclosed. Also disclosed are methods of creating and using the inventive multilayer structure. | 04-05-2012 |
20120080614 | PHOTOLYTICALLY AND ENVIRONMENTALLY STABLE MULTILAYER STRUCTURE FOR HIGH EFFICIENCY ELECTROMAGENTIC ENERGY CONVERSION AND SUSTAINED SECONDARY EMISSION - A multilayer structure for authentication that includes an energy conversion layer, at least one stability enhancement layer and at least one optical variable element is disclosed. Also disclosed are methods of creating and using the inventive multilayer structure for use-in authentication. | 04-05-2012 |
20120080615 | PHOTOLYTICALLY AND ENVIRONMENTALLY STABLE MULTILAYER STRUCTURE FOR HIGH EFFICIENCY ELECTROMAGENTIC ENERGY CONVERSION AND SUSTAINED SECONDARY EMISSION - A multilayer structure for use in authentication that includes an energy conversion, at least one stability enhancement layer and at least one blocking layer is disclosed. Also disclosed are methods of creating and using the inventive multilayer structure for use in authentication. | 04-05-2012 |
20130088853 | ILLUMINATION DELIVERY SYSTEM FOR GENERATING SUSTAINED SECONDARY EMISSION - An illumination delivery system for generating sustained secondary emission that includes at least an illumination source, a waveguide, and one or more energy conversion layers is disclosed. Also disclosed are methods of using the inventive illumination delivery system for generating sustained secondary emission. | 04-11-2013 |
20130175456 | PHOTOLYTICALLY AND ENVIRONMENTALLY STABLE MULTILAYER STRUCTURE FOR HIGH EFFICIENCY ELECTROMAGNETIC ENERGY CONVERSION AND SUSTAINED SECONDARY EMISSION - Disclosed is a method for converting a primary electromagnetic radiation to a longer output wavelength that includes providing an energy conversion layer having a first photoluminescent material and a second photoluminescent material, exposing the energy conversion layer to the primary electromagnetic radiation, and transferring at least a portion of absorbed energy from the first photoluminescent material to the second photoluminescent material by dipolar coupling, such that the second photoluminescent material subsequently emits the longer output wavelength. | 07-11-2013 |
20130288022 | Chromic Luminescent Compositions and Textiles - A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile. | 10-31-2013 |
20130288075 | CHROMIC LUMINESCENT OBJECTS - A chromic luminescent object comprising one or more chromic luminescent compositions incorporated into or onto one or more portions of the object, in which the one or more chromic luminescent compositions are selected such that, when subsequently exposed to incident electromagnetic radiation, at least brightness of the one or more portions of the object is substantially modulated through absorption and emission as a function of incident electromagnetic radiation is disclosed. Also disclosed are methods for fabricating the chromic luminescent object. | 10-31-2013 |
20140103258 | CHROMIC LUMINESCENT COMPOSITIONS AND TEXTILES - A chromic luminescent composition and method for fabricating the composition are disclosed. The chromic luminescent composition comprises at least one or more non-luminescent materials and one or more luminescent materials. The one or more non-luminescent materials having absorption spectra that at least partially overlap with the spectrum of incident electromagnetic radiation. The one or more luminescent materials convert at least a portion of energy of incident electromagnetic radiation to a lower energy wavelength. The one or more non-luminescent materials and the one or more luminescent materials are selected such that, when subsequently exposed to incident electromagnetic radiation, color and brightness are substantially modulated through absorption and emission as a function of incident electromagnetic radiation. Also disclosed are a chromic luminescent textile and a method for fabricating the textile. | 04-17-2014 |
20140366796 | Time Validation Indicator - A time validation indicator is disclosed comprising at least a receiving layer and an activating layer. The receiving layer comprises at least one or more masking colorants and one or more deactivators that cause and maintain the one or more masking colorants in an initial colored state. The activating layer comprises at least one or more migratory activators that migrate into the receiving layer upon at least a portion of the receiving layer being placed in contact with at least a portion of the activating layer to initiate a predetermined time period. The migration of the one or more migratory activators into the receiving layer causes at least a portion of the one or more masking colorants to advance to a final colorless state resulting in a visual color change of the receiving layer that indicates the predetermined time period has elapsed. Also disclosed are methods for creating and using the inventive time validation indicator. | 12-18-2014 |
20150041683 | Luminous Systems - A luminous system comprising one or more illumination sources, a multilayer structure, and one or more diffuse reflection layers being optically decoupled from the multilayer structure, wherein the emission and the reflection of the luminous system produce a first observed visible color when the one or more illumination sources are powered and a second observed visible color when the one or more illumination sources are non-powered is disclosed. Also disclosed are methods of creating the inventive luminous system. | 02-12-2015 |